Merck May Buy Smart Cells for More Than $500 Million, WSJ Says

Merck & Co. may buy SmartCells Inc., the closely-held biotechnology company that is developing a diabetes treatment, for more than $500 million if certain conditions are met, the Wall Street Journal reported, citing an unidentified person familiar with the situation.

The acquisition may be announced tomorrow, the newspaper said.

To contact the editor responsible for this story: Jeran Wittenstein at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.